Medications for Mantle Cell Lymphoma (MCL)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mantle Cell Lymphoma (MCL).
Found 5 Approved Drugs for Mantle Cell Lymphoma (MCL)
Bortezomib
Brand Names
Velcade, Boruzu
Bortezomib
Brand Names
Velcade, Boruzu
Form: Injection
Method of administration: Intravenous, Subcutaneous
FDA approval date: May 13, 2003
Classification: Proteasome Inhibitor
Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma.
Revlimid
Generic Name
Lenalidomide
Revlimid
Generic Name
Lenalidomide
Form: Capsule
Method of administration: Oral
FDA approval date: December 27, 2005
Classification: Thalidomide Analog
IND ICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone.
Calquence
Generic Name
Acalabrutinib
Calquence
Generic Name
Acalabrutinib
Form: Tablet
Method of administration: Oral
FDA approval date: August 04, 2022
Classification: Kinase Inhibitor
CALQUENCE is a kinase inhibitor indicated: In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
Brukinsa
Generic Name
Zanubrutinib
Brukinsa
Generic Name
Zanubrutinib
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: November 14, 2019
Classification: Kinase Inhibitor
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Jaypirca
Generic Name
Pirtobrutinib
Jaypirca
Generic Name
Pirtobrutinib
Form: Tablet
Method of administration: Oral
FDA approval date: January 27, 2023
Classification: Kinase Inhibitor
JAYPIRCA is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances